{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:17:40Z","timestamp":1791245860463,"version":"4.1.0"},"reference-count":111,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1517\/13543776.2014.880692","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T08:10:51Z","timestamp":1390551051000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":36,"title":["Retinoid X receptor ligands: a patent review (2007 \u2013 2013)"],"prefix":"10.1517","volume":"24","author":[{"given":"Shoya","family":"Yamada","sequence":"first","affiliation":[{"name":"Okayama University Graduate School of Medicine, Division of Pharmaceutical Sciences, Dentistry and Pharmaceutical Sciences","place":["Japan"]},{"name":"Research Fellowship Division, Japan Society for the Promotion of Science","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kakuta","sequence":"additional","affiliation":[{"name":"Okayama University Graduate School of Medicine, Division of Pharmaceutical Sciences, Dentistry and Pharmaceutical Sciences","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(92)90014-Z"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.2.121"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022566"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.7"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.1.30"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/mend.16.5.0823"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.7.8.1153"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.00328.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.13.6157"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/np100120c"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.166215"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90199-X"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00119-9"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/me.2003-0148"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119852109"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.6"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00164-2"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.18.8154-8166.2004"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.01.049"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.01.047"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.041609298"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000248101.93488.84"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.09.014"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.6.1324"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114508894408"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.06.010"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000099786.99623.EF"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0278"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2005.04.008"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200004200"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020340q"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020401k"},{"key":"e_1_3_2_35_1","unstructured":"Hamilton Brook Smith & Reynolds P.C. Retinoid X receptor moderators. US0090860A1; 2008"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313223200"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0830671100"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506982103"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0026-895X(24)09245-9","article-title":"Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents","volume":"59","author":"Singh Ahuja H","year":"2001","unstructured":"Singh Ahuja H, Liu S, Crombie DL, et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 2001;59:765-73","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2397"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505853200"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1581"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904083401404"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.8.8930"},{"key":"e_1_3_2_45_1","unstructured":"Ortho-McNeil Pharmaceutical Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators. US075864A1; 2009"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml300055n"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1021\/jm400033f","article-title":"Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carbox ylic acid and structural development to increase potency","volume":"56","author":"Ohsawa F","year":"2013","unstructured":"Ohsawa F, Yamada S, Yakushiji N, et al. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carbox ylic acid and structural development to increase potency. J Med Chem 2013;56:1865-77","journal-title":"J Med Chem"},{"key":"e_1_3_2_48_1","unstructured":"University Okayama. Nuclear receptor ligand. JP111588A; 2010"},{"key":"e_1_3_2_49_1","unstructured":"University Okayama. RXR partial agonist. JP177329A; 2013"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12864"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.06.080"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.metabol.2004.11.013","article-title":"A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions","volume":"54","author":"Yotsumoto T","year":"2005","unstructured":"Yotsumoto T, Naitoh T, Kanaki T, et al. A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions. Metabolism 2005;54:573-8","journal-title":"Metabolism"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.3001"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00016a018"},{"key":"e_1_3_2_55_1","unstructured":"Scientifique Centre National de la Recherche RXR-PPARgamma agonist\/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer. WO070379A1; 2010"},{"key":"e_1_3_2_56_1","unstructured":"Fish & Richardson PC. Method and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators. US093546A1; 2009"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/carcin\/bgg090","article-title":"Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid","volume":"24","author":"Matsushima-Nishiwaki R","year":"2003","unstructured":"Matsushima-Nishiwaki R, Okuno M, Takano Y, et al. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003;24:1353-9","journal-title":"Carcinogenesis"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.01045.x"},{"key":"e_1_3_2_59_1","first-page":"7675","article-title":"Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma","volume":"61","author":"Matsushima-Nishiwaki R","year":"2001","unstructured":"Matsushima-Nishiwaki R, Okuno M, Adachi S, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-82","journal-title":"Cancer Res"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1349-7006.2007.00621.x","article-title":"Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta","volume":"98","author":"Yoshimura K","year":"2007","unstructured":"Yoshimura K, Muto Y, Shimizu M, et al. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci 2007;98:1868-74","journal-title":"Cancer Sci"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-191"},{"key":"e_1_3_2_62_1","unstructured":"Wyeth. Use of RXR agonists for the treatment of osteoarthritis. WO102789A2; 2009"},{"key":"e_1_3_2_63_1","unstructured":"Io Therapeutics Inc. Autoimmune disorder treatment using RXR agonists. WO090616; 2013"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200700313"},{"key":"e_1_3_2_65_1","unstructured":"University Okayama. Rexinoid compound having alkoxy group. WO105386A1; 2008"},{"key":"e_1_3_2_66_1","unstructured":"University Okayama. Anti-allergic agent comprising RXR agonist as active ingredient. WO041449; 2010"},{"key":"e_1_3_2_67_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JAD-2000-2214","article-title":"Elimination of amyloid beta neurotoxicity","volume":"2","author":"Blanchard BJ","year":"2000","unstructured":"Blanchard BJ, Hiniker AE, Lu CC, et al. Elimination of amyloid beta neurotoxicity. J Alzheimers Dis 2000;2:137-49","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"e_1_3_2_68_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1471-4159.2011.07459.x","article-title":"Activation of alpha-secretase cleavage","volume":"120","author":"Postina R","year":"2012","unstructured":"Postina R. Activation of alpha-secretase cleavage. J Neurochem 2012;120(Suppl 1):46-54","journal-title":"J Neurochem"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220484110"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209085200"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1217697"},{"key":"e_1_3_2_72_1","unstructured":"University Case Western Reserve. RXR agonists compounds and methods. WO056232A2; 2013"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235809"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234089"},{"key":"e_1_3_2_75_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1233937","article-title":"Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d","volume":"340","author":"Tesseur I","year":"2013","unstructured":"Tesseur I, Lo AC, Roberfroid A, et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science 2013;340:924-e","journal-title":"Science"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235505"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234114"},{"key":"e_1_3_2_78_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-8-18","article-title":"Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice","volume":"8","author":"LaClair KD","year":"2013","unstructured":"LaClair KD, Manaye KF, Lee DL, et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice. Mol Neurodegener 2013;8:18","journal-title":"Mol Neurodegener"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(02)00253-6"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2012.03.029"},{"key":"e_1_3_2_81_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0091-6749(99)70513-0","article-title":"The prevalence of allergic disease and linoleic acid in the diet","volume":"103","author":"Black PN","year":"1999","unstructured":"Black PN. The prevalence of allergic disease and linoleic acid in the diet. J Allergy Clin Immunol 1999;103:351-2","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/68.1.142"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.39"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M504611200"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2005.74"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-06-0047"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm788"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01683"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.12.007"},{"key":"e_1_3_2_90_1","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1194\/jlr.R800059-JLR200","article-title":"Diabetes and atherosclerosis: is there a role for hyperglycemia?","volume":"50","author":"Chait A","year":"2009","unstructured":"Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 2009;50 Suppl:S335-9","journal-title":"J Lipid Res"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0666"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03830.x"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0087"},{"key":"e_1_3_2_94_1","first-page":"2219","article-title":"Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats","volume":"6","author":"Ooi GT","year":"1992","unstructured":"Ooi GT, Tseng LY, Tran MQ, et al. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992;6:2219-28","journal-title":"Mol Endocrinol"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.912"},{"key":"e_1_3_2_96_1","first-page":"318","article-title":"Effects of insulinlike growth factor binding proteins on insulin-like growth factor-I biodistribution in tumor-bearing nude mice","volume":"41","author":"Sun BF","year":"2000","unstructured":"Sun BF, Kobayashi H, Le N, et al. Effects of insulinlike growth factor binding proteins on insulin-like growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med 2000;41:318-26","journal-title":"J Nucl Med"},{"key":"e_1_3_2_97_1","first-page":"1771","article-title":"Paired pulse ratio analysis of insulin-induced synaptic plasticity in the snail brain","volume":"216","author":"Murakami J","year":"2013","unstructured":"Murakami J, Okada R, Fujito Y, et al. Paired pulse ratio analysis of insulin-induced synaptic plasticity in the snail brain. J Exp Biol 2013;216:1771-3","journal-title":"J Exp Biol"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2236-04.2004"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.02.040"},{"key":"e_1_3_2_100_1","article-title":"Type 2 diabetes mellitus and Alzheimer's disease: from physiopathology to treatment implications","author":"Moreira RO","year":"2013","unstructured":"Moreira RO, Campos SC, Soldera AL. Type 2 diabetes mellitus and Alzheimer's disease: from physiopathology to treatment implications. Diabetes Metab Res Rev 2013; In press, doi: 10.1002\/dmrr.2442","journal-title":"Diabetes Metab Res Rev"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-0007"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s4397"},{"key":"e_1_3_2_103_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.ejhg.5201811","article-title":"Insights into modern disease from our distant evolutionary past","volume":"15","author":"Yngvadottir B","year":"2007","unstructured":"Yngvadottir B. Insights into modern disease from our distant evolutionary past. Eur J Hum Genet 2007;15:603-6","journal-title":"Eur J Hum Genet"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000603400301"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/570848"},{"key":"e_1_3_2_106_1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1248\/bpb.28.744","article-title":"The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain","volume":"28","author":"Hayashi H","year":"2005","unstructured":"Hayashi H, Tohda M, Watanabe H, et al. The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain. Biol Pharm Bull 2005;28:744-6","journal-title":"Biol Pharm Bull"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S38318"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.12.2625"},{"key":"e_1_3_2_109_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0006-2952(95)00183-Z","article-title":"Diminished teratogenicity of retinoid X receptor-selective synthetic retinoids","volume":"50","author":"Jiang H","year":"1995","unstructured":"Jiang H, Penner JD, Beard RL, et al. Diminished teratogenicity of retinoid X receptor-selective synthetic retinoids. Biochem Pharmacol 1995;50:669-76","journal-title":"Biochem Pharmacol"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10646-012-0900-9"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml100184k"},{"key":"e_1_3_2_112_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1248\/bpb.35.629","article-title":"Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice","volume":"35","author":"Kakuta H","year":"2012","unstructured":"Kakuta H, Ohsawa F, Yamada S, et al. Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice. Biol Pharm Bull 2012;35:629-33","journal-title":"Biol Pharm Bull"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.2"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543776.2014.880692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:50:26Z","timestamp":1772761826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543776.2014.880692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1517\/13543776.2014.880692"],"URL":"https:\/\/doi.org\/10.1517\/13543776.2014.880692","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}